Evidence map›Paper›PMID 31584845›Full record

ArticleHuman vaccines & immunotherapeutics2020

Parental risk factors for fever in their children 7-10 days after the first dose of measles-containing vaccines.

Ousseny Zerbo, Sharareh Modaressi, Kristin Goddard, Edwin Lewis, Karin Bok, Hayley Gans, Nicola P Klein

Open access · hybridAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Article
  3. Vaccinomics: a cross-sectional survey of public values.Human vaccines & immunotherapeutics · 2021
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Ousseny ZerboDivision of Research, Vaccine Study Center, Kaiser Permanente Northern California, Oakland, CA, USA.
Sharareh ModaressiDivision of Research, Vaccine Study Center, Kaiser Permanente Northern California, Oakland, CA, USA.
Kristin GoddardDivision of Research, Vaccine Study Center, Kaiser Permanente Northern California, Oakland, CA, USA.
Edwin LewisDivision of Research, Vaccine Study Center, Kaiser Permanente Northern California, Oakland, CA, USA.
Karin BokUS Department of Health and Human Services, National Vaccine Program Office, Office of the Assistant Secretary for Health, Washington, DC, USA.
Hayley GansDepartment of Pediatrics, Stanford University, Stanford, CA, USA.
Nicola P KleinDivision of Research, Vaccine Study Center, Kaiser Permanente Northern California, Oakland, CA, USA.ORCID 0000-0003-1777-4814
Kaiser Permanente · USOffice of the Assistant Secretary for Health · USStanford University · US

Funding

Effect of Maternal Influenza Vaccination during Pregnancy on Risk of Infant InfluenzaK01AI139275 · NIAID · KAISER FOUNDATION RESEARCH INSTITUTE · PI ZERBO, OUSSENY · 2018 to 2022
$648k
NIAID NIH HHS K01 AI139275
6 · The paper itself

Abstract

We evaluated whether parental clinical conditions were associated with fever after a first dose of measles-containing vaccine (MCV) in the child in a cohort study including 244,125 children born in Kaiser Permanente Northern California between 2009 and 2016 who received MCV between ages 1 and 2 years. Each child was linked with his/her mother and father when possible. Parental clinical conditions present before and after their child's birth were identified. We defined fever in the children as clinic and emergency department visits with a fever code 7-10 days after a first dose of MCV ("MCV-associated fever"). We evaluated parental clinical conditions associated with MCV-associated fever using multivariate logistic regression analyses. After adjusting for multiple factors, including healthcare utilization, maternal fever [odds ratio (OR) = 1.19, 95% confidence interval (CI) 1.06-1.32], fever after MCV (OR = 5.90, 95% CI 1.35-25.78), respiratory infections (OR = 1.20, 95% CI 1.10-1.31), migraine (OR = 1.14, 95% CI 1.05-1.24), syncope (OR 1.14, 95% CI 1.01-1.27), and essential thrombocythemia (OR = 1.93, 95% CI 1.15-3.25) were significantly associated with MCV-associated fever. Paternal respiratory infections (OR = 1.15, 95% CI 1.05-1.27), fever associated with respiratory infections (OR = 1.47, 95% CI 1.23-1.76), and vitiligo (OR = 1.63, 95% CI 1.06-2.53) were significantly associated with MCV-associated fever. Parental clinical conditions, specifically fever alone and fever associated with respiratory infection, are associated with fever in their child 7-10 days after MCV.

Indexed as

MeaslesMeasles-Mumps-Rubella VaccineChickenpox VaccineChildChild, PreschoolCohort StudiesFemaleHumansInfantMaleRisk FactorsVaccines, CombinedChickenpox VaccineMeasles-Mumps-Rubella VaccineVaccines, Combinedclinical factorsFeverMMR/MMRVparentalrisk factorsvaccine

Identifiers

PMID31584845
PMCPMC7227709
OpenAlexW2977427531

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.